Cutaneous lupus erythematosus
MONDO:0005282An autoimmune disorder that manifests as different lupus-specific skin disorders; it can occur with systemic lupus erythematosus, or as a singular disease.
Also known as: lupus erythematosus, cutaneous
76 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Continued anifrolumab treatment studied for lupus and related diseases
Disease control Not yet recruitingThis study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a malaria pill tame discoid lupus?
Disease control Not yet recruitingThis study tests whether dihydroartemisinin, a drug used for malaria, can help treat discoid lupus erythematosus (DLE), a chronic skin condition causing red, scaly patches. Researchers will compare two doses of the drug to a standard lupus treatment (hydroxychloroquine) in 100 ad…
Phase: PHASE2 • Sponsor: Kunming Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New lupus drug candidate enters early human safety testing
Disease control Not yet recruitingThis early-stage study tests a new medicine called HC022 in 32 adults with lupus (SLE or CLE). The main goal is to see if the drug is safe and how the body handles it. Participants will receive multiple doses or a placebo, and researchers will monitor for side effects and measure…
Phase: PHASE1 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill aims to tame painful lupus skin flares
Disease control Not yet recruitingThis study is testing whether a pill called enpatoran can safely reduce active skin rashes in people with lupus. About 202 participants with moderate-to-severe lupus skin symptoms will take either enpatoran or a placebo pill for 24 weeks, while continuing their standard lupus med…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 02, 2026 00:00 UTC
-
Could a single injection tame the immune system in lupus?
Knowledge-focused Not yet recruitingThis early-stage trial is testing a single injection of an experimental drug called SHR-7012 in healthy adults. The main goal is to check how safe and tolerable the drug is, and how the body absorbs and processes it. The study involves about 50 participants aged 18 to 55, who wil…
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New lupus drug candidate begins first safety tests in humans
Knowledge-focused Not yet recruitingThis early-stage study will test the safety and tolerability of a new drug called ACT100 in 48 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. This is the first …
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC